Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR, TSX:TKM) is a leading RNA interference (RNAi) therapeutics company. With more than 14 years of industry experience, Tekmira is a global leader in the RNAi field. We are developing novel drugs in areas where there is a significant unmet medical need and commercial opportunity. We also license our leading lipid nanoparticle (LNP) delivery technology to partners around the world.
Tekmira's 2014 AGM and Proxy Materials are now available on our website.